Association of XRCC3 and XPD751 SNP with response to platinum-based chemotherapy in advanced NSCLC patients.

Abstract

e18045 Background: The purpose of this study was to investigate whether X-ray repair cross-complementing group 3 alleles Thr241Met, xeroderma pigmentosum group D variant alleles Lys751Gln affected clinical outcomes of 1st line platinum-based chemotherapy in advanced non-small cell lung cancer patients. Methods: 355 patients enrolled into this study and their genotyping of X-ray repair cross-complementing group 3 Thr241Met,xeroderma pigmentosum group D Lys751Gln were detected by the TaqMan assay plus the real time PCR method in theri peripheral blood lymphocytes. SPSS version 12.0 was used to do the X2 and Kaplan-Meier survival analysis. Results: The median age was 59.5 years old and 68.5% of the patients were male. No relationship was found between the wild-type, heterozygous and homozygous polymorphic variants SNPs of XRCC3 241, XPD751 and genders, ages, histology, smoking status. Progression free survival (PFS) and overall survival (OS) were similar between the patients with wild-type, heterozygous and homozygous polymorphic variants of XRCC3 and XPD751. However, in the subgroup analysis, OS in the patients with XRCC3 C/C was significant longer than the patients with C/T or T/T in the vinorelbine subgroup(14.0m vs 9.3m, P=0.042)and the taxanes subgroup (18.5m vs 7m, P=0.01). Conclusions: XRCC3 gene Polymorphisms may play different roles to predict the efficacy of platinum-based doublet chemotherapy according to different chemotherapy regimen, which warrant further prospective large-scale study.